Entries by Dan Zapata

La Jolla Pharmaceutical Company Announces First Quarter 2016 Financial Results and Recent Corporate Progress

SAN DIEGO–(BUSINESS WIRE)– La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today reported first quarter 2016 financial results and highlighted recent corporate progress. Recent Corporate Progress La Jolla’s ATHOS (Angiotensin II for the […]

La Jolla Pharmaceutical Company to Provide Corporate Overview at the Cowen and Company 36th Annual Health Care Conference

SAN DIEGO–(BUSINESS WIRE)– La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that the Company will provide a corporate overview at the Cowen and Company 36th Annual Health Care Conference taking place March 7–9 […]

La Jolla Pharmaceutical Company Announces Fourth Quarter and Full Year 2015 Financial Results and Highlights Corporate Progress

SAN DIEGO–(BUSINESS WIRE)–La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today reported fourth quarter and full year 2015 financial results and highlighted 2015 corporate progress. La Jolla Pharmaceutical Company Announces Fourth Quarter and […]

La Jolla Pharmaceutical Company to Provide Corporate Overview at the 2016 BIO CEO & Investor Conference

SAN DIEGO–(BUSINESS WIRE)– La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that the Company will provide a corporate overview at the 2016 BIO CEO & Investor Conference taking place February 8–9 […]

La Jolla Pharmaceutical Company Announces Notice of Allowance for U.S. Patent Covering LJPC-501

Nov. 30, 2015 13:00 UTC La Jolla Pharmaceutical Company Announces Notice of Allowance for U.S. Patent Covering LJPC-501 Patent Term Extends to 2034 SAN DIEGO–(BUSINESS WIRE)– La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening […]

La Jolla Pharmaceutical Company Announces Third Quarter 2015 Financial Results and Recent Corporate Progress

SAN DIEGO–(BUSINESS WIRE)– La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today reported third quarter 2015 financial results and highlighted recent corporate progress. Recent Corporate Progress La Jolla initiated a Phase 1 clinical […]

La Jolla Pharmaceutical Company Doses First Patient in Phase 1 Clinical Trial of LJPC-401 in Patients at Risk of Iron Overload

La Jolla Pharmaceutical Company Doses First Patient in Phase 1 Clinical Trial of LJPC-401 in Patients at Risk of Iron Overload SAN DIEGO–(BUSINESS WIRE)– La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today […]

La Jolla Pharmaceutical Company Closes Offering of Common Stock

La Jolla Pharmaceutical Company Closes Offering of Common Stock SAN DIEGO–(BUSINESS WIRE)– La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the “Company” or “La Jolla”), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced the closing of its underwritten public offering of 2,932,500 shares of […]

La Jolla Pharmaceutical Company Receives Positive Opinion from European Orphan Committee for LJPC-401

La Jolla Pharmaceutical Company Receives Positive Opinion from European Orphan Committee for LJPC-401 EMA Innovation Task Force Meeting Granted SAN DIEGO–(BUSINESS WIRE)– La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the “Company” or “La Jolla”), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that […]

La Jolla Pharmaceutical Company Announces Pricing of Underwritten Offering of Common Stock

La Jolla Pharmaceutical Company Announces Pricing of Underwritten Offering of Common Stock SAN DIEGO–(BUSINESS WIRE)– La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the “Company” or “La Jolla”), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced the pricing of an underwritten offering of 2,550,000 […]